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Abstract
Background: Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression
regulation, being involved in diverse epigenetic processes. They are aberrantly expressed in various tumors, but their
exact role in bladder cancer is still obscure. We have recently found a major role of the Polycomb repression complex in
recurrence of non-muscle-invasive bladder cancer. Here, we report the xpression of Polycomb-related lncRNAs:antisense
noncoding RNA in the INK4 locus (ANRIL) and HOX antisense intergenic RNA (HOTAIR) in these tumors.
Findings: We studied a dataset of non-invasive bladder cancer samples by quantitative reverse transcription PCR
(RT-qPCR) and analyzed also invasive bladder cancer samples using TCGA data. Our results showed that, while ANRIL
seemed not to have a determining role, an increased HOTAIR expression appeared in recurrent and high-graded
tumors associated with poor prognosis. In addition, through genome-wide transcriptome analyses, we
observed that HOTAIR-EZH2-complex-regulated genes can efficiently discriminate between non-tumoral,
recurrent, and non-recurrent bladder cancer samples. We also observed a significant correlation between EZH2 and
HOTAIR expression levels. Using overexpression, knockdown, and pharmacological approaches in bladder cancer cell
lines, we also observed that EZH2 regulates HOTAIR expression.
Conclusions: Our findings indicate that HOTAIR expression has prognostic value for bladder cancer progression,
recurrence, and survival and suggest that HOTAIR plays active roles in modulating the cancer epigenome, becoming an
interesting candidate as a target for cancer diagnosis and therapy. The observed HOTAIR regulation by EZH2 and the
possibility of modulating EZH2 activity with specific inhibitors open new possible paths to be explored in bladder
cancer therapy.
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Findings
Background
In the past decades, little progress has been achieved in
the development of biomarkers for bladder cancer (BC), in
spite of its high prevalence and of being a leading cause of
cancer-associated deaths in developed countries. At diag-
nosis, 75 % of cases are categorized as superficial tumors,
Ta or T1 (localized in the mucosa or submucosa, referred
as non-muscle-invasive bladder cancer: NMIBC) while
25 % are already invasive cancer, T2–T4 (muscle-invasive
bladder cancer: MIBC). In the case of NMIBC, recur-
rences are frequent, requiring continuous surveillance and
becoming one of the most costly cancers to treat. Despite
its lower prevalence, MIBC is typically associated with a
relatively poor prognosis (5-year survival ranging from 30
to 70 %). The current gold-standard treatment, in the best
of the cases, is the surgical removal of the bladder, with
the subsequent impairment in quality of life, followed by
radio-chemotherapy [1, 2].
RNA molecules of more than 200 nucleotides in length
and a lack of protein-coding potential are collectively
referred to as long non-coding RNAs (lncRNAs) [3]. Re-
cently, increasing evidence suggests that lncRNAs regulate
key pathways in cancer [4], constituting attractive novel
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prognostic markers and therapeutic targets [3]. Most
lncRNAs function with DNA-binding proteins, such as
chromatin-modifying complexes, and epigenetically
regulate the expression of multiple genes [5].
LncRNA HOX antisense intergenic RNA(HOTAIR) is
transcribed in the antisense direction from the HOXC gene
cluster [6] and recruits Polycomb Repression Complex 2
(PRC2) to specific target genes genome-wide, leading to
H3K27 trimethylation and epigenetic silencing of gene
expression [7]. HOTAIR has been shown to be upregulated
in cancer tissues and metastases, and its expression level
correlates in general with metastasis and poor outcome in
multiple cancer types [3–5, 7–10].
ANRIL is another example of lncRNA that is claimed
as a participant directly in epigenetic transcriptional
repression [11, 12]. ANRIL is transcribed from the
INK4B-ARF-INK4A gene locus and binds to CBX7
[12], which belongs to Polycomb Repression Complex 1
(PRC1), to control the expression of p16INK4a, p15INK4b,
and p14ARF tumor suppressor genes [13]. ANRIL also
binds SUZ12, recruiting PRC2, and repressing the expres-
sion of the p15INK4B locus [14]. Based on these data,
ANRIL would play dual roles, serving as a scaffold for both
PRC1 and PRC2, as shown for HOTAIR [15].
Recently, we provided evidence from human patient
samples and a novel transgenic mouse model that EZH2,
the catalytic subunit of PRC2, mediates recurrence in
NMIBC through gene expression modulation [16]. Here,
we report the expression analysis of HOTAIR and ANRIL,
which cooperate with PRC2 to allow specific gene repres-




A series of 85 NMIBC patients has been analyzed and
consecutively evaluated at the Urology Department of the
University Hospital “12 de Octubre,” between October
2009 and December 2012 (Additional file 1: Table S1).
Samples were collected by multiple cold-cup biopsies
from the exophytic part of the tumor and from distant
normal mucosa of the bladder of patients undergoing
TUR. All samples were kept in RNAlater. Informed con-
sent was obtained from all patients, and the study was
approved by the Ethical Committee for Clinical Research
of University Hospital “12 de Octubre.” Samples and
united data from patients included in this study were pro-
vided by the Biobanco iþ12 in the Hospital 12 de Octubre
integrated in the Spanish Hospital Biobanks Network
(RetBioH; www.redbiobancos.es) following standard oper-
ation procedures with appropriate approval of the by the
Ethical Committee for Clinical Research of University
Hospital “12 de Octubre” (CEIC 10/50). The construc-
tion of a tissue microarray and analysis of EZH2
expression by immunohistochemistry has been re-
ported elsewhere [16, 17].
RT-qPCR
Total RNA was isolated using miRNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions, and DNA
was eliminated (RNAse-Free DNAse Set Qiagen). Reverse
transcription was performed from 10 ng of total RNA and
using the Omniscript RT Kit (Qiagen) and specific primers
for all genes of interest. PCR was performed in a 7500 Fast
Real Time PCR System using Go Taq PCR master mix
(Promega) and 1 μL of cDNA as a template. Melting
curves were performed to verify specificity and absence of
primer dimers. Reaction efficiency was calculated for each
primer combination, and the TBP gene was used as the
reference gene for normalization [18]. The sequences of
the specific oligonucleotides used are listed in Additional
file 1: Table S2.
Whole transcriptome analysis
Genome-wide transcriptome experiments using the
Affymetrix HuGene-1_0-st-v1 microarray have been
previously reported [16], and datasets have been depos-
ited in GEO (GSE38264).
Cell cultures
Ten bladder cancer cell lines (Additional file 1: Table S3),
kindly provided by Dr. FX Real (CNIO, Spain) [19], were
maintained in DMEM GlutaMAX™ (Gibco-BRL Life
Technologies) with 10 % fetal bovine serum (Hyclone)
and 1 % antibiotic-antimycotic (Gibco-BRL Life Technolo-
gies) at 37 °C in a humidified atmosphere of 5 % CO2. Six
different drugs (NVP-BEZ35 50 nM (LC Laboratories),
Rapamycin 50 nM (LC Laboratories), Thyrphostin 100 μM
(Sigma-Aldrich), Sb31542 10 nM (Sigma-Aldrich), DZNep
10 μM (Sigma-Aldrich), PD98059 10 μM (Sigma-Aldrich))
targeting key pathways (mTOR, Stat3, TGFβ, EZH2, and
MAPK/ERK, respectively) were applied on a MGH-U4
non-muscle-invasive cell line for 6 h. In addition, DZNeP
(10 μM) treatment was also applied at different time dura-
tions (0, 6, 24, and 48 h). For the knockdown of EZH2, the
5637 cell line was transduced with lentivirus-based shRNA
(MISSION® shRNA, Sigma Aldrich) targeting human EZH2
gene (two independent shRNA constructs: TRCN000035
3069 and TRCN0000286227). Cells were selected by puro-
mycin (0.5 μg/mL; Sigma-Aldrich) resistance for 2 weeks,
and pooled clones were collected. For the increased expres-
sion of EZH2, the RT112 cell line was transfected, using
FuGENE®6 Transfection Reagent (Promega), with an
EZH2-coding plasmid under CMV promoter. Transfected
cells were selected by growing in the presence of hygro-
mycin (250 μg/mL; Sigma-Aldrich), and pooled clones
were collected.
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Western blot
Pelleted cells were disrupted by freeze-thawing cycles in
lysis buffer [200 mmol/L 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid, pH 7.9, 25 % glycerol, 400 mmol/L
NaCl, 1 mmol/L EDTA, 1 mmol/L ethylene glycol tetraace-
tic acid, 1 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mmol/L
phenylmethylsulfonylfluoride, 20 mmol/L NaF, 1 mmol/L
NaPPi, 1 mmol/L Na3VO4, 2.5 mmol/L dithiothreitol] and
centrifuged to obtain supernatant containing total protein.
Thirty-five micrograms of protein per sample was resolved
in SDS-PAGE and transferred to nitrocellulose membranes
(Amersham). Membranes were blocked with 0.1 % Tween-
20 with 5 % bovine serum albumin (BSA) diluted in TBS
and incubated with the appropriate antibodies diluted in
TBS-T 0.5 % BSA. Secondary antibodies were purchased
from Jackson Immuno Research. Super Signal West Pico
Chemiluminescence Substrate (Pierce) was used according
to the manufacturer’s recommendations to visualize
the bands. Antibodies used are against EZH2 (Abnova
MAB9542), AKT-P-Ser473 (Epitomics 2118-1), AKT-
P-Thr308 (Cell Signaling 4056), and ERK-P-1/2 (Cell
signaling 4370). Loading was controlled by using anti-
GAPDH antibody (Santa Cruz sc-25778) and anti-ACTIN
antibody (Santa Cruz sc-1616).
Statistical analysis
Comparisons were performed using the Wilcoxon-Mann-
Whitney test (for two groups), Limma test, and the Student
t-test for paired samples showing normal distribution. For
multiple groups, the Kruskal-Wallis test followed by Dunn’s
multiple comparison test was used. Correlations were
calculated using Pearson correlation coefficient. Survival
analyses (recurrence-free or overall survival), according to
various variables, were performed using the Kaplan-Meier
method, and differences between the patient groups were
tested by the log-rank test. p values less than 0.05 were con-
sidered statistically significant. Discrimination between
samples showing increased or decreased gene expression
was made using the median. Overlapping significance was
monitored by exact Fisher test. SPSS 17.0, R statistical soft-
ware v2.15.1, and Graph prism5.0 software were used for
processing of data. In the figures, p values are provided as
follows: *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.0001.
Results and discussion
Expression of HOTAIR in NMIBC
High expression levels of HOTAIR have been proven to
correlate with metastasis and poor prognosis in many
types of cancer [15]. However, its role during bladder
oncogenesis is still to be clarified. In the present study,
we determined the gene expression levels of HOTAIR,
PRC2 members (EZH2, SUZ12, EED), and BMI1 (PRC1)
by qPCR in a series of NMIBC patients (n = 64). We
observed a significant and positive correlation between
HOTAIR and all PRC2 members and BMI1 (Fig. 1a and
Additional file 2: Figure S1A–C). Regarding the HOTAIR
gene levels, we observed that compared to normal paired
samples its levels were increased in tumors regardless
their different grades (Fig. 1b) or stages (Fig. 1c). This
finding is in agreement with other cancers [4, 5, 20, 21]
and with a recently reported study of bladder cancer
from a Chinese population [22].
Expression of ANRIL in NMIBC
No data are available on the possible role of ANRIL in BC.
Since it mediates silencing p15INK4b by binding to
SUZ12 [14], and p16INK4a locus through CBX7 (a PRC1
component) recruitment [12], which is frequently silenced
in BC [23], we analyzed its expression in our patient data-
set. The qPCR data revealed, as in the case of HOTAIR, a
significant positive correlation between ANRIL and all
PRC2 members and BMI-1 (Fig. 1d and Additional file 2:
Figure S1D–F). However, no differences were found
between normal and tumor samples regardless their grade
(Fig. 1e) or stage (Fig. 1f).
HOTAIR mediates recurrence and progression in NMIBC
The high frequency of recurrence is a current clinical
problem in NMIBC. To analyze whether ANRIL or
HOTAIR expression could be a recurrence determinant,
we characterized their expression in primary tumors
that have subsequently developed recurrence or not
after a follow-up period (Additional file 1: Table S1). In
the case of ANRIL, its expression levels could not dis-
criminate between recurrent and non-recurrent tumors
(Additional file 3: Figure S2). This lack of correlation,
together with the previous results, showing no major
differences in normal and tumor samples or according
tumor clinicopathological characteristics, supports that
this lncRNA does not seem to have a major role in
NMIBC.
Interestingly, recurrent tumors showed a significantly
higher HOTAIR expression in comparison with non-
recurrent tumors (Fig. 2a). In fact, when patients were
stratified according high or low HOTAIR levels (above or
below median), those patients with higher HOTAIR expres-
sion exhibited significantly earlier recurrence (Fig. 2b).
HOTAIR recruits the PRC2 complex to specific target
genes, which leads to H3K27 trimethylation and epigen-
etic silencing, and a large number of genes have been
previously identified by the binding of HOTAIR-EZH2
complexes [7, 24]. We thus used this gene dataset in our
previous genome-wide transcriptome data of human
NMIBC samples [16]. Remarkably, the expression of the
HOTAIR-EZH2 target genes could efficiently discrimin-
ate between recurrent and non-recurrent tumors, as well
as non-tumor bladder tissue in an unsupervised manner
(Fig. 2c). These results reinforce that the altered gene
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expression programs displayed by NMIBC with a high-
recurrence probability are mediated by HOTAIR-EZH2
complexes. Therefore, our current results indicated that
HOTAIR might be a potential prognostic biomarker for
recurrence.
Tumor progression, defined as an increased tumor
stage or grade in recurrences, is a common clinical
problem in the management of BC. In our series, 11
out of 33 patients (Additional file 1: Table S1) displayed
tumor progression. To analyze whether increased
HOTAIR expression could define a progression bio-
marker, we determined the HOTAIR levels in recurrent
samples according to the tumor progression. We found
that primary tumors in patients displaying tumor pro-
gression were characterized by increased HOTAIR
levels (Fig. 2d). Similarly, those patients with high
HOTAIR expression exhibited significantly (p = 0.03)
earlier progression in recurrences (Fig. 2e).
HOTAIR expression in MIBC
Since in our patient sample series (see Additional file 1:
Table S1) there is a higher representation of non-
muscle-invasive bladder cancer samples (87 %) com-
pared to T2 samples (n = 11), we also prompted to
analyze any potential roles of HOTAIR expression in
muscle-invasive (T2–4) tumors. To this, we have used
the RNA-seq data available at the TCGA Data Portal
(https://tcga-data.nci.nih.gov/tcga/). We observed no sig-
nificant differences between normal and tumor samples
(Fig. 3a), probably due to the low representation of normal
bladder samples in this dataset. The comparison between
grades was not possible since all the samples available
for RNA-seq analyses with clinical information are
high grade. In the case of stages, a significant increase
(p = 0.006) in HOTAIR expression was found accord-
ing to cancer progression (Fig. 3b), finding higher
levels when the cancer spreads across muscle layers
(T2 stage) to the surrounding organs (T4). These re-
sults suggest that HOTAIR is a potential epigenetic
marker of the molecular stages of bladder cancer.
Finally, the Kaplan-Meier analysis showed that
patients who had higher HOTAIR expression (above
median) had significantly shorter overall survival than
those with lower expression (Fig. 3c). This finding
Fig. 1 Expression of lncRNAs HOTAIR and ANRIL in NMIBC. a qPCR analyses showing the correlation between EZH2 and HOTAIR expression in 64
NMIBC samples. b,c qPCR analyses showing the expression of HOTAIR in normal and NMIBC samples according the tumor grade (b) and stage (c).
d qPCR analyses showing the correlation between EZH2 and ANRIL expression in 64 NMIBC samples. e,f qPCR analyses showing the expression of
ANRIL in normal and NMIBC samples according the tumor grade (e) and stage (f ). Correlations were calculated using Pearson correlation
coefficient. Comparisons between gene expression levels were done using the Kruskal-Wallis test followed by Dunn’s multiple comparison.
p values are provided as follows: *p < 0.05; **p < 0.01; ***p < 0.005. TBP was used as normalizer gene [18]
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Fig. 2 (See legend on next page.)
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indicates that HOTAIR could represent a powerful in-
dependent prognostic factor of malignant progression,
recurrence, and overall survival rate in BC. Similar
findings have been recently reported for several other
types of cancer [4, 5, 7, 8, 20, 21].
The role of methylation
Since methylation of HOTAIR has already been reported
[25], we wondered if these differences in HOTAIR expres-
sion could be due to differences in HOTAIR methylation.
Using Illumina HumanMethylation450 Array data from the
Fig. 3 HOTAIR expression in MIBC from the TCGA portal. a Expression of HOTAIR in normal and MIBC tumor samples. Comparison was performed
by Limma test. b Expression of HOTAIR in MIBC samples according tumor stage. Comparison was performed by Limma test. c Kaplan-Meier analysis of
MIBC patient overall survival according HOTAIR expression (median discrimination) (p value was obtained by the log-rank test). RNA-seq data were
downloaded from the TCGA portal (https://tcga-data.nci.nih.gov/tcga/)
(See figure on previous page.)
Fig. 2 HOTAIR mediates recurrence and progression in NMIBC. a qPCR analyses showing the expression of HOTAIR in NMIBC samples according
the tumor recurrence. b Kaplan-Meier analysis showing that patients with higher HOTAIR expression (according the median) showed an earlier
recurrence (p value was obtained by the log-rank test). c Heat map showing the distribution of genes (rows) and samples following unsupervised
clustering (Pearson correlation and average linkage method) of 28 tumors and 10 normal samples [16] according the expression of genes
previously identified by the binding of HOTAIR-EZH2 complexes [7, 24]. A red (overexpressed) to blue (downregulated) scheme following
the above scale limits (in log2 scale) is shown. Note that recurrent and non-recurrent tumors, besides of non-tumor bladder tissue, could
be efficiently discriminated. d qPCR analyses showing the expression of HOTAIR in recurrent NMIBC samples according the tumor progression.
e Kaplan-Meier analysis showing that patients with higher HOTAIR expression (according the median) showed an earlier progression upon
recurrence (p value was obtained by the log-rank test)
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TCGA portal, no relevant DNA methylation differences
were found between normal and tumor samples along the
HOTAIR gene body (Additional file 4: Figure S3A). Using
the same system, when normal and tumor samples were
checked in a different patient dataset, including our low-
grade samples and high-grade samples from UCL (per-
sonal communication), again no significant differences
were found (Additional file 4: Figure S3B). Similarly, the
comparison between low- and high-grade tumor samples
showed no significant differences in HOTAIR methylation;
the differences are even smaller (Additional file 4: Figure
S3C). These results indicate that DNA methylation, at
least regarding the assayed sites, cannot determine the
differences in HOTAIR expression between normal tissue
and tumors or between low- and high-grade tumors.
Functional evidence of association between EZH2 and
HOTAIR expression
The precise regulatory mechanisms affecting HOTAIR
expression are still largely unknown. The positive cor-
relation observed between EZH2 and HOTAIR levels
(Fig. 1a) might indicate a co-regulatory process.
Similarly, we observed a trend of positive correlation
in samples showing high EZH2 protein expression
(Additional file 5: Figure S4).
Fig. 4 Functional evidence of HOTAIR regulation by EZH2. a Expression of EZH2 protein as assessed by immunoblot in the quoted non-invasive
bladder cancer cell lines in parallel with HOTAIR (bar graph, assessed by RT-qPCR). b Expression of EZH2 protein (immunoblot) and HOTAIR (bar
graph) in 5637 MIBC cell lines upon knockdown mediated by two different shRNA constructs. c Expression of EZH2 protein (immunoblot) and
HOTAIR (bar graph) in RT112 NMIBC cell line upon transfection with CMV-EZH2-coding plasmid. d Expression of the quoted proteins and HOTAIR
(bar graph) in MGH-U4 NMIBC cell line upon treatment (24 h) with NVP-BEZ35 (50 nM), rapamycin (50 nM), tyrphostin (100 μM), SB31542 (10 nM),
DZNeP (10 μM), and PD98059 (10 μM). Note that HOTAIR expression is only significantly reduced upon treatment with the EZH2-specific inhibitor
DZNeP. e Expression of EZH2 protein (immunoblot) and HOTAIR (bar graph) in MGH-U4 NMIBC cell line upon treatment for different time periods
with DZNeP (10 μM). GAPDH and ACTIN were used for loading control in immunoblots, and TBP was used as a normalizer gene for RT-qPCR
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The analysis of HOTAIR and EZH2 expression in
nine different non-invasive bladder cancer cell lines
also showed that those cells showing high EZH2 pro-
tein levels also displayed high HOTAIR expression
(Fig. 4a), thus reinforcing their co-regulation. To test
whether EZH2 could modulate HOTAIR expression, we
performed knockdown of EZH2 in 5637 cells (a MIBC
cell line showing the highest EZH2 expression; not
shown). We observed that the reduction of EZH2 is
accompanied with a substantial reduction of HOTAIR
levels (Fig. 4b). Similarly, the increased expression of
EZH2 by transfection of RT112 cells is also in parallel
with increased expression of HOTAIR (Fig. 4c). These
findings indicate that EZH2 could regulate the expres-
sion of HOTAIR.
We next studied the effect of various pharmaco-
logical inhibitors (described in the “Subjects and
methods” section) of several key cancer signal trans-
duction pathways in the MGH-U4 cell line. We ob-
served that only the EZH2-specific inhibitor DZNep
[26, 27] produced a significant decrease in HOTAIR
expression (Fig. 4d). In agreement, the treatment with
DZNep for different time periods within these cells,
revealed that 6 h of treatment, was sufficient to lower
HOTAIR levels (Fig. 4e). These results suggest that
the activity of EZH2 is required to modulate HOTAIR
expression. However, whether this regulation is exe-
cuted directly or indirectly remains to be elucidated
in the future.
Conclusions
Differential regulation of long non-coding RNAs has
been reported in different types of cancer although
their functional mechanisms are still unknown and
intriguing. Our experiments show a poor involve-
ment of ANRIL in BC, while confirming an upregu-
lation of HOTAIR gene expression levels in recurrent
and high-graded tumors associated with a poor prog-
nosis, in both NMIBC and MIBC. In this context,
we have recently shown that EZH2 mediates recur-
rence in NMIBC, being also upregulated in tumor
samples and especially in recurrent tumors [16].The
current study gives an insight into the regulation of
HOTAIR, indicating that EZH2 may regulate
HOTAIR expression. This finding might have thera-
peutic implications for the treatment of recurrent
NMIBC, since there are several EZH2 inhibitors in
preclinical studies that can be of interest as thera-
peutic tools in tumors showing increased HOTAIR
expression. The present data also indicate that such
inhibition may result in decreased HOTAIR levels,
favoring the rewiring of gene expression as a pos-
sible therapeutic strategy.
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